Yu-Ming Ying

Safety and Efficacy Evaluation of 4SCAR19 Chimeric Antigen Receptor-Modified T Cells Targeting B Cell Acute Lymphoblastic Leukemia - Three-Year Follow-up of a Multicenter Phase I/II Study

Lung-Ji Chang, Shih-Ting Tsao, Huyong Zheng, 2016 .

BRD4 degrader ARV-825 produces long-lasting loss of BRD4 protein and exhibits potent efficacy against cholangiocarcinoma cells.

Zhenqing Feng, Yang Li, X. Zou, 2019, American journal of translational research.